Articles

The Process and the Ps

The funny thing about for-profit companies is that their stakeholders expect them to make—are you ready for it—a profit. And for the majority of industries around the globe, people universally accept this fact. It is interesting, therefore, to look at the healthcare industry where the existence of a for-profit model is less widely accepted or at least is tinged with outcries for profit but not profiteering.
Written byRandall C Willis
| 3 min read

The funny thing about for-profit companies is that their stakeholders expect them to make—are you ready for it—a profit. And for the majority of industries around the globe, people universally accept this fact.

It is interesting, therefore, to look at the healthcare industry where the existence of a for-profit model is less widely accepted or at least is tinged with outcries for profit but not profiteer­ing. Because health is very personal, the discus­sion of profit in this sector has become rancor­ous. So rancorous, in fact, that the industry has been forced to respond, whether because of personal reflections from within or social and governmental pressures from without.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.